Sotalol Dose Optimization for Fetal Tachycardia: A Pregnancy Physiologically Based Pharmacokinetic Model Study
Prenatal Diagnosis · 2026-04 · 46 (4) · 533-540
DOI: 10.1002/pd.70104 ↗At a glance
Journal article in Prenatal Diagnosis, published online on 2026-02-27. Written by Hedwig van Hove and 6 co-authors. Institution: Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands. Major MEDLINE topics: Sotalol, Models, Biological, Tachycardia, Anti-Arrhythmia Agents. Cited 1 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY 4.0). Funded by: Gates Foundation, Bill and Melinda Gates Foundation.
Abstract (original language)
Objective
To establish an optimized sotalol dosing strategy for fetal tachycardia using a pregnancy physiologically based pharmacokinetic (PBPK) model.
Method
A verified PBPK model was developed incorporating pregnancy‐induced physiological changes and placental transfer. Simulations were performed to evaluate current dosing recommendations and alternative dosing scenarios were explored. To avoid maternal dose‐related toxicity (QT‐prolongation), we aimed for maternal concentrations < 2.5 mg/L. Based on neonatal concentration‐effect data, we aimed for fetal C trough concentrations of 0.4–1.0 mg/L.
Results
Model predictions for maternal and fetal plasma concentrations were generally consistent with available maternal and fetal exposure data. Simulations showed that at the maximum oral daily dose of 480 mg, 16% of maternal concentrations exceeded the toxicity threshold, while 90% of fetuses had therapeutic C trough levels. Reducing the daily dose to 400 mg lowered maternal overexposure to 0.1%, with 87% of fetuses still reaching therapeutic levels. Additionally, splitting the 480 mg dose into three administrations per day reduced maternal overexposure to 0.3% and increased fetal target attainment to 95%.
Conclusion
Pregnancy PBPK modeling is a valuable tool for optimizing fetal sotalol therapy. A daily dose not exceeding 400 mg, or dividing daily doses of 240 mg and higher into three administrations, may optimize the balance between predicted fetal efficacy and maternal toxicity risk.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Neonatal and Pediatric Intensive Care, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
- Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands.
ORCID profiles: Hedwig van Hove
Funding
- Gates Foundation
- Bill and Melinda Gates Foundation
Cite
APA
van Hove, H., van der Heijden, J. E. M., van Uden, A., Gijsen, V. M. G. J., Greupink, R., de Wildt, S. N., & van Drongelen, J. (2026). Sotalol Dose Optimization for Fetal Tachycardia: A Pregnancy Physiologically Based Pharmacokinetic Model Study. Prenatal Diagnosis, 46(4), 533-540. https://doi.org/10.1002/pd.70104
Vancouver
van Hove H, van der Heijden JEM, van Uden A, Gijsen VMGJ, Greupink R, de Wildt SN, et al. Sotalol Dose Optimization for Fetal Tachycardia: A Pregnancy Physiologically Based Pharmacokinetic Model Study. Prenatal Diagnosis. 2026;46(4):533-540. doi:10.1002/pd.70104
BibTeX
@article{vanHove2026,
author = {van Hove, Hedwig and van der Heijden, Joyce E M and van Uden, Anne and Gijsen, Violette M G J and Greupink, Rick and de Wildt, Saskia N and van Drongelen, Joris},
title = {Sotalol Dose Optimization for Fetal Tachycardia: A Pregnancy Physiologically Based Pharmacokinetic Model Study},
journal = {Prenatal Diagnosis},
year = {2026},
volume = {46},
number = {4},
pages = {533--540},
doi = {10.1002/pd.70104}
}
EUVIMED